Axitinib versus sorafenib in advanced renal cell carcinoma: Subanalyses by prior therapy from a randomised phase III trial Journal Article


Authors: Escudier, B.; Michaelson, M. D.; Motzer, R. J.; Hutson, T. E.; Clark, J. I.; Lim, H. Y.; Porfiri, E.; Zalewski, P.; Kannourakis, G.; Staehler, M.; Tarazi, J.; Rosbrook, B.; Cisar, L.; Hariharan, S.; Kim, S.; Rini, B. I.
Article Title: Axitinib versus sorafenib in advanced renal cell carcinoma: Subanalyses by prior therapy from a randomised phase III trial
Abstract: Background:In the AXIS trial, axitinib prolonged progression-free survival (PFS) vs sorafenib in patients with advanced renal cell carcinoma (RCC) previously treated with sunitinib or cytokines.Methods:In post hoc analyses, patients were grouped by objective response to prior therapy (yes vs no), prior therapy duration (< vs ≥median), and tumour burden (baseline sum of the longest diameter < vs ≥median). PFS and overall survival (OS), and safety by type and duration of prior therapy were evaluated.Results:Response to prior therapy did not influence outcome with second-line axitinib or sorafenib. PFS was significantly longer in axitinib-treated patients who received longer prior cytokine treatment and sorafenib-treated patients with smaller tumour burden following sunitinib. Overall survival with the second-line therapy was longer in patients who received longer duration of prior therapy, although not significant in the sunitinib-to-axitinib sequence subgroup; OS was also longer in patients with smaller tumour burden, but not significant in the cytokine-to-axitinib sequence subgroup. Safety profiles differed modestly by type and duration of prior therapy.Conclusions:AXIS data suggest that longer duration of the first-line therapy generally yields better outcome with the second-line therapy and that lack of response to first-line therapy does not preclude positive clinical outcomes with a second-line vascular endothelial growth factor-targeted agent in patients with advanced RCC. © 2014 Cancer Research UK.
Keywords: sorafenib; renal cell carcinoma; axitinib; vegf receptor inhibitor; prior therapy
Journal Title: British Journal of Cancer
Volume: 110
Issue: 12
ISSN: 0007-0920
Publisher: Nature Publishing Group  
Date Published: 2014-05-13
Start Page: 2821
End Page: 2828
Language: English
DOI: 10.1038/bjc.2014.244
PROVIDER: scopus
PMCID: PMC4056058
PUBMED: 24823696
DOI/URL:
Notes: Br. J. Cancer -- Export Date: 8 July 2014 -- CODEN: BJCAA -- Source: Scopus
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors
  1. Robert Motzer
    1243 Motzer